礼来替尔泊肽中国上市 GLP-1市场激战正酣

北京商报
02 Jan

本就火爆的国内GLP-1(胰高血糖素样肽-1)药物市场再添一员。1月2日,礼来官宣葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂替尔泊肽(商品名:穆峰达)正式在中国上市,同时覆盖两项适应症,包括二型糖尿病和减重。据悉,穆峰达是全球首个且目前唯一获批用于二型糖尿病和长期体重管理的每周一次GIP/GLP-1受体激动剂。减重版替尔泊肽在2024年前三季度收入30.18亿美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10